Newsroom

澳大利亚悉尼--(BUSINESS WIRE)--(美国商业资讯)-- 作为一家可提供全方位服务的国际知名临床合同研究组织 (CRO) 和科学咨询公司，Novotech（诺为泰）于今日发布了一份全新白皮书《早期肿瘤学——临床研究格局与CRO推动因素 (2025)》，深入剖析了塑造早期肿瘤学发展的关键驱动因素。 约60%的肿瘤学药物的临床应用能从I期推进至II期，但最终仅3-6%能获得机构监管批准。白皮书概述了影响取得早期阶段成功的关键因素，包括试验设计、受试者筛选及区域性发展路径。 白皮书指出，澳大利亚持续在全球首次人体试验（FIH）及早期临床研究领域保持重要地位。其以伦理为导向的审查框架支持在大约4至8周内启动临床试验，加之成熟的FIH中心、肿瘤学研究网络及成本效益优势，使澳大利亚成为项目后续拓展至美国、欧洲及更广阔的亚洲市场的实际启动基地。 该分析为生物技术和制药申办方提供了有关现代试验方法、基于精准治疗的策略以及全球协调执行方式如何塑造早期肿瘤学研究格局的详细分析。白皮书还强调，诺为泰凭借科学的专业知识、监管合规性以及全球5500多家临床试验中心，为这些项目提供大力支持。 重点内...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--The Marygold Companies, Inc. (NYSE American: MGLD), a global holding firm specializing in financial services, today announced that its wholly owned subsidiary, USCF Investments (USCF), has launched the USCF Oil Plus Bitcoin Strategy Fund (NYSE Arca: WTIB). This new exchange-traded fund (ETF) represents a significant milestone for USCF, marking its first venture into cryptocurrency within its extensive portfolio of alternative investment products. For furth...

澳洲雪梨--(BUSINESS WIRE)--(美國商業資訊)-- 作為一家可提供全方位服務的國際知名臨床受託研究機構 (CRO) 和科學諮詢公司，Novotech於今日發佈了一份全新白皮書《早期階段腫瘤醫學：臨床研究格局與CRO推動因素 (2025)》，深入剖析了塑造早期階段腫瘤醫學發展的關鍵驅動因素。 約60%的腫瘤學藥物的臨床應用能從第I期推進至第II期，但最終僅3-6%能獲得機構監管核准。白皮書概述了影響取得早期階段成功的關鍵因素，包括試驗設計、受試者篩選及區域性發展路徑。 白皮書指出，澳洲持續在全球首次人體試驗 (FIH) 及早期階段臨床研究領域保持重要地位。其以倫理為導向的審查框架支援在大約4至8週內啟動臨床試驗，加之成熟的FIH中心、腫瘤醫學研究網絡及成本效益優勢，使澳洲成為臨床計畫後續拓展至美國、歐洲及更廣闊的亞洲市場的實際啟動基地。 該分析為生物技術和製藥委託方提供了有關現代試驗方法、基於精準治療的策略以及全球協調執行方式如何塑造早期階段腫瘤醫學研究格局的詳細分析。白皮書還強調，Novotech憑藉科學的專業知識、監管合規性以及全球5500多家臨床試驗中心，為這些計畫...

SYDNEY--(BUSINESS WIRE)--Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing e...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy....

COEUR D’ALENE, Idaho--(BUSINESS WIRE)--Genius Gourmet, a leader in innovative functional protein beverages and snacks, today announced the official launch of its newest SKU, Sparkling Protein – Fruit Punch, now available across key retailers including Target, Sam's Club, Meijer, and H-E-B. The Fruit Punch offering becomes the brand’s second sparkling protein flavor, delivering a refreshing, lightly carbonated beverage with 30 grams of protein and 0g sugar, available in single cans, 4-Pack, and...

BOSTON--(BUSINESS WIRE)--PAN, a global, integrated, data-driven marketing and PR agency for B2B tech and healthcare brands, today announced the launch of its new B2B Web Services offering. The new capabilities expand the agency’s integrated marketing services with a modern, analytics-led approach to website strategy, design, messaging, development, and long-term optimization. This announcement builds on years of website strategy, copywriting, design, and development that naturally emerged from...

HANGZHOU, China--(BUSINESS WIRE)--Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. The upgraded version of AQ now features three core capabilities: health Q&A, AI health companion, and integrated health services. Launched in June 2025, AQ has rapidly grown to 15 million monthly active users, making it China’s lead...

ATENAS, Grecia--(BUSINESS WIRE)--  COMUNICADO DESTINADO EXCLUSIVAMENTE A MEDIOS DE COMUNICACIÓN MÉDICOS Y FARMACÉUTICOS EUROPEOS, Y A MEDIOS DE COMUNICACIÓN FINANCIEROS EUROPEOS GENESIS Pharma, biofarmacéutica regional dedicada a la comercialización de medicamentos innovadores en Europa Central y Oriental, acaba de anunciar la firma de un acuerdo exclusivo con Otsuka Pharmaceutical Europe Ltd. (OPEL), filial europea de la empresa sanitaria global Otsuka Pharmaceutical Co., Ltd., para comerciali...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NYSE Arca Biotechnology UCITS ETF 12.12.2025 FBTU.LN IE00BL0L0H60 525,002.00 USD 13,443,866.87 25.607  ...